Jade Biosciences, Inc.
No enriched coverage for $JBIO in the last 7 days.
No SEC Form 4 filings for $JBIO in the last 30 days.
Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K NASDAQ false 0001798749 0001798749 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001798749 0001798749 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
Boundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
Recent JBIO coverage spans market movers, corporate actions and financial news.
The 8-K discloses a new, milestone-based licensing obligation and royalty economics that can change near-term cash needs and longer-term revenue expectations.
Board/compensation update adds governance and clinical leadership signal, but no direct operational or financial guidance is provided.
Clinical readouts and forward trial initiation dates can materially affect valuation via updated efficacy/safety expectations.
Corporate governance/bylaws update tied to a security-holder vote; likely low immediate earnings/valuation impact but can affect meeting mechanics and voting rights.
Dilutive equity issuance provides near-term funding but can pressure valuation and near-term trading as float increases.
alphai scores every news story that mentions JBIO with an AI model for sentiment and relevance, and aggregates insider trades from Jade Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K NASDAQ false 0001798749 0001798749 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
4 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001798749 0001798749 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
3 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-3.3 4 d161530dex33.htm EX-3.3 EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF JADE BIOSCIENCES, INC. (a Nevada corporation) (effective as of June 9, 2026) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office . The registered office of Jade Biosciences, Inc., a Nevada co
2 min readJade Biosciences (Nasdaq: JBIO) said it closed its public offering of 11.5 million shares of common stock, including 1.5 million shares from the underwriters’ full option. Shares were sold at $15.00 each, raising $172.5 million in gross proceeds. Jade plans to use net proceeds for clinical trials, preclinical studies, manufacturing, and R&D, plus working capital and general corporate purposes.
2 min readU.S. stock futures were mixed Thursday after a lower close Wednesday: Nasdaq 100 and S&P 500 rose, while Dow gained. Treasury yields were 4.49% (10-year) and 4.07% (2-year). CME FedWatch showed a 96.2% chance the Fed holds rates in June. CrowdStrike jumped on a 4-for-1 split; PVH fell 20.54% on guidance. Lululemon was up ahead of earnings.
6 min readJade Biosciences (Nasdaq: JBIO) priced a public offering of 10,000,000 shares of common stock at $15.00 per share, raising expected gross proceeds of $150.0 million before underwriting discounts and expenses. The offering is set to close June 5, 2026, with a 30-day option for up to 1,500,000 additional shares. Net proceeds will fund clinical trials, preclinical studies, manufacturing, and R&D.
2 min readJade Biosciences’ JBIO fell Monday after investors questioned limited quantitative disclosure on anti-drug antibodies (ADAs), according to William Blair. The company’s interim analysis of JADE101 showed a 700 mg dose cut IgA by ~70% vs baseline, sustained through 12 weeks. Modeling suggests 350 mg SC maintenance every 12 weeks could keep IgA reductions above 70% with four injections/year. Jade expects Phase 3 to start in H1 2027 and interim JUNIPER data in 2027; it said ADAs have not affected ph
5 min readJade Biosciences’ shares (JBIO) fell about 12% in Monday morning trading after the company reported positive Phase 1 trial data for JADE101 in immunoglobulin A nephropathy. The stock was quoted at $18.35, down $2.69 (12.77%) from the prior close of $21.04 on Nasdaq.
3 min readJade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min read
